VJHemOnc Podcast

Managing and treating GvHD and other post-transplant complications

Feb 23, 2023

Experts Charles Craddock, Shernan Holtan, and Anna Sureda discuss GvHD and other post-transplant complications. They highlight the importance of addressing these complications and explore approaches to GvHD prophylaxis and treatment including regenerative medicine and different drug strategies.

09:45

Creator website

Episode guests

Shernan Holtan

Charles Craddock

Anna Sureda

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Post-transplant complications, including graft versus host disease (GVHD), can significantly impact patient quality of life, highlighting the importance of addressing these complications.

Novel approaches are being explored to minimize the risk of GVHD and improve the overall success of allogeneic stem cell transplantation (alloSCT), with a focus on reducing the risk of relapse and improving patient quality of life.

Deep dives

Importance of Addressing Post Transplant Complications and GVHD

Post transplant complications, including graft versus host disease (GVHD), can significantly impact patient quality of life. Patients often face psychological stress and complexities during induction chemotherapy and the transplant process. The focus is shifting towards reducing the risk of relapse and improving quality of life. There is a need for more research on interventions to decrease psychological morbidity, as well as strategies for GVHD prophylaxis and treatment.

Introduction

3min

Unmet needs in graft versus host disease and future considerations for treatment

5min

Approaches to Graft-Versus-Host Disease Prophylaxis and Treatment

2min

Graft-versus-host disease (GvHD) is a common complication associated with allogeneic stem cell transplantation (alloSCT), and can occur in acute and chronic forms. Novel approaches are being explored to minimize the risk of GvHD and improve the overall success of alloSCT.

In this podcast, you will hear from experts Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, and Christopher Kanakry, MD, National Cancer Institute, Bethesda, MD, who discuss the importance of addressing post-transplant complications, and further highlight current approaches to GvHD prophylaxis and treatment.

The post Managing and treating GvHD and other post-transplant complications appeared first on VJHemOnc.